Physician profile
Matthew Biever
NPI 1023227741
$73,720.15
in general payments reported to CMS, 2019-2025
32 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $456 · 2021: $1,346 · 2022: $16K · 2023: $27K · 2024: $16K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Consulting Fee: $15K · Food and Beverage: $5,595 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,200 · Honoraria: $1,700 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,033.75 |
| Consulting Fee | $14,600.00 |
| Food and Beverage | $5,595.15 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,200.00 |
| Honoraria | $1,700.00 |
| Education | $235.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39,108.89 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $19,997.16 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $8,299.98 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,438.10 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $862.73 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $783.51 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $783.38 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $737.73 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $334.27 | 2019-2025 | Trintellix |
| Lundbeck LLC | $246.52 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $227.08 | 2020-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $154.97 | 2020-2024 | Jornay Pm |
| Allergan, INC. | $124.48 | 2020 | |
| Supernus Pharmaceuticals, INC. | $82.77 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $78.68 | 2023-2025 | Azstarys |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $66.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $57.80 | 2024-2025 | Cobenfy |
| Indivior INC. | $47.46 | 2019-2023 | Perseris |
| Noven Pharmaceuticals, INC. | $27.82 | 2022 | |
| Almatica Pharma LLC | $26.84 | 2022 | |
| Adlon Therapeutics L.P. | $24.89 | 2021 | |
| Noven Therapeutics, LLC | $23.65 | 2022 | |
| Sage Therapeutics, LLC | $22.35 | 2024 | |
| Vertical Pharmaceuticals, LLC | $22.14 | 2024 | Relexxii |
| Neuronetics, INC. | $20.91 | 2023 | Neurostar Tms Therapy System |
| Jazz Pharmaceuticals INC. | $20.52 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.78 | 2019 | |
| Collegium Pharmaceutical, INC. | $19.25 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $17.04 | 2019 | |
| Shire North American Group INC | $16.04 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.55 | 2024 | Quviviq |
| Tris Pharma INC | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Biever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.